Replies to post #508819 on Anavex Life Sciences Corp (AVXL)

[boi568]

Your point may have even more force if neither of rapporteurs were neurologists.

In any event, in a re-examination Anavex can (and should) request the involvement of an EMA Science Advisory Group, which would include experts in this field.

Regarding ADL, we have no indication that CHMP has seen the recent OLE analyses, one of which reported stat sig ADL results (early versus late starters) at 144 weeks.

[abew4me]

Quote: "...But maybe there is a neurologist or two on the CHMP who understands the irrelevance of the second endpoint in early alz,
who realizes what a breakthrought a safe oral medicine would be.
A medicine that saves millions from a slow agony of death.
And he or she is fighting to get the CHMP to delay the decision so they can think out of the box, so they can appreciate the ABCLEAR data.
That is what negative trend indicated to me"

LOL...that's a lot of wishful thinking in my opinion. You sound like you're grasping for straws...which is surprising to me. I'm not going to risk anymore of my hard-earned money on THAT scenario.

I've sold almost all of my shares in AVXL...and reinvested in ANVS.

Good luck.

abe

PS...I've almost recouped my losses from AVXL with ANVS. It's kicking azz!